Results 61 to 70 of about 7,789 (204)

Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis

Journal of Dermatological Treatment
Background Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice.Objectives To identify ...
Teppei Hagino, Mai Yoshida, Risa Hamada, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda   +5 more
doaj   +1 more source

Upadacitinib (Rinvoq)

, 2023
CADTH
openalex   +2 more sources

Treatment of atopic dermatitis with upadacitinib: adcare single center experience

Frontiers in Medicine
IntroductionThe role of upadacitinib in the management of moderate to severe atopic dermatitis seems promising, but more data on its efficacy and safety are needed.
Daria S. Fomina, Daria S. Fomina, Olga A. Mukhina, Valeria I. Mikhailova, Marina S. Lebedkina, Elizaveta L. Sedova, Elena N. Bobrikova, Olga G. Elisyutina, Olga G. Elisyutina, Elena S. Fedenko, Tair T. Nurpeisov, Tair T. Nurpeisov, Alexander V. Karaulov, Mar’yana A. Lysenko, Mar’yana A. Lysenko, Luis Felipe C. Ensina   +15 more
doaj   +1 more source

Clinical features and comorbidity patterns in early and very early rheumatoid arthritis: Insights from a China nationwide survey

Rheumatology &Autoimmunity, EarlyView.
Haojie Xu, Liyun Zhang, Yuehong Huo, Rui Wu, Lijun Wu, Ling Lei, Linyu Geng, Chunyu Tan, Xiaomei Li, Ru Li, Yin Su, the Women's Rheumatoid Arthritis Research Collaborative Group   +11 more
wiley   +1 more source

Erosion Regression in Patients with RA After Upadacitinib-A Pilot Study Using High Resolution Peripheral Quantitative Computed Tomography

Journal of Clinical Rheumatology and Immunology
Background: Janus kinases inhibitor (JAKi) is a potent drug in treating patients with rheumatoid arthritis (RA). However, the effect of JAKi on finite structural changes remained uncertain.
Isaac T Cheng, Ho So, Evelyn H Chow, Qihan Wu, Martin Li, Vivian W Hung, Ling Qin, Chun Kwok Wong, Lai Shan Tam   +8 more
doaj   +1 more source

Efficacy of Upadacitinib in a Middle‐Aged Man With Netherton Syndrome Refractory to Dupilumab: A Case Report

The Journal of Dermatology, EarlyView.
Bo‐Jie Yu, Pei‐Ling Li, Bing‐Sian Lin, Shou‐En Wu, Chih‐Tsung Hung   +4 more
wiley   +1 more source

Safety of upadacitinib in atopic dermatitis in randomized clinical trials across 6 years

Journal of the European Academy of Dermatology and Venereology, EarlyView.
The current study found no evidence of cumulative increased safety risks with upadacitinib 15 or 30 mg for up to 6 years and over 9000 patient‐years of safety data in adults and adolescents. There were low rates of adjudicated major adverse cardiovascular events, adjudicated thromboembolic events and malignancies. Abstract Background Atopic dermatitis (
Christopher G. Bunick, Alan D. Irvine, Jonathan I. Silverberg, Emma Guttman‐Yassky, Mona Shahriari, Xinghua Gao, Stephan Weidinger, Norito Katoh, Namita Vigna, Deanne M. Dilley, Elvira D'Andrea, Henrique D. Teixeira, Andrew M. Platt, Gweneth F. Levy   +13 more
wiley   +1 more source

Dupilumab‐Associated Palmar Erythema Successfully Treated With Fluconazole

Australasian Journal of Dermatology, EarlyView.
Katina J. Selvaraj, Geoffrey Lee
wiley   +1 more source

Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Achieving rapid control of itch in atopic dermatitis and prurigo nodularis may minimize symptomatology and disease burden. Analysis of clinical trials in atopic dermatitis and prurigo nodularis showed significantly more patients in nemolizumab versus placebo groups achieved a meaningful clinical response in itch within 48 h, and separation increased ...
Sonja Ständer, Sarina B. Elmariah, Shawn G. Kwatra, Gil Yosipovitch, Andrew E. Pink, Soo Yeon Cheong, Xiaoxiao Chen, Zarif K. Jabbar‐Lopez, Liliana Ulianov, Christophe Piketty, Jonathan I. Silverberg   +10 more
wiley   +1 more source

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

BMC Rheumatology, 2018
Background Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis.
Julie M. Parmentier, Jeff Voss, Candace Graff, Annette Schwartz, Maria Argiriadi, Michael Friedman, Heidi S. Camp, Robert J. Padley, Jonathan S. George, Deborah Hyland, Matthew Rosebraugh, Neil Wishart, Lisa Olson, Andrew J. Long   +13 more
doaj   +1 more source